| Name | Title | Contact Details |
|---|
CMA Technology Solutions is a Baton Rouge, LA-based company in the Computers and Electronics sector.
Exertis is the leading technology distributor of consumer, business and enterprise products from established and emerging technology brands, and a wholly owned subsidiary of parent company DCC PLC, a FTSE 100 company. After 38 years of profitability Exertis continues to outperform the market, achieving revenues of £3.631billion in FY2019. Exertis is proud to be part of DCC plc; an ambitious and entrepreneurial FTSE 100 company. DCC plc employ approximately 12,500 people across four divisions and operate in 17 countries. To find out more visit www.dcc.ie. The Exertis group’s scale, knowledge and experience in the technology sector and complete end-to-end product portfolio enable us to deliver innovative solutions and market leading services for our partners. Exertis’ market leading position, state of the art logistics and range of value add services and solutions ensures we deliver more for our customers.
Amnet Computer & Network Svc is a Colorado Springs, CO-based company in the Computers and Electronics sector.
WonderFi is on a mission to simplify and streamline access to the assets and technology that power the new era of decentralized finance. A proprietary dashboard which integrates with the entire DeFi ecosystem, WonderFi is technology-first organization that has a data driven approach in creating and capturing value in the DeFi ecosystem - through both assets and technology.
Cota is a technology platform that enables providers, payers, and life science companies involved in diagnosing and treating complex diseases to optimize the care of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Address™ (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.